# Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)

Source: https://onco.cc/trials/nct06102161/  
OnCo record `nct06102161` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in lung cancer, run by Fudan University, not yet recruiting.

## Summary

Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020) is a phase 3, interventional study registered as NCT06102161 by Fudan University, with a registry enrolment figure of 286 participants, started 2023-11 and due to reach its primary completion in 2025-11. Interventions recorded: Wedge resection. Conditions listed: Lung Cancer; Wedge Resection; Ground-glass Opacity. Primary outcome: 5-year overall survival. Lung eligibility wording from the registry: "Not receiving lung cancer surgery before;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06102161
- Phase: 3
- Setting: Wedge Resection for Ground-glass Opacity-featured Lung Cancer With Size Less Than 2cm and Consolidation-to-tumor Ratio Between 0.25 to 0.5: a Single-arm, Multi-center, Prospective, Confirmatory Phase III Trial
- Sponsor: Fudan University
- Enrolled: 286

## Sources

- ClinicalTrials.gov NCT06102161: https://clinicaltrials.gov/study/NCT06102161

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06102161.json